Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRPa cancer immunology treatment BI 770371 Read more
Navidea Biopharmaceuticals, Inc. Announces Results of Exploratory Analysis Completed on July 2, 2024 Read more
CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities Read more
Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer Read more
Carisma Therapeutics Granted FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid Tumors Read more
Lilly collaborates with OpenAI to discover novel medicines to treat drug-resistant bacteria Read more